Dose-Dense Sequentials Chemotherapy with Epirubicin and Paclitaxel in Advanced Breast Cancer

REFERENCES

• Bonadonna G., Gianni L., Santoro A., Bonfante V., Bidoli P., Casali P., Demicheli R., Valagussa P. Drugs Ten Years Later: Epirubicin. Ann. Oncol. 1993; 4: 359–369
   PubMed Web of Science ®Google Scholar
• Wilson W. H., Berg S. L., Bryant G., Wittes R. E., Bates S., Fojo A., Steinberg S. M., Goldspiel B. R., Herdt J., O'Shaughnessy J., Balis F. M., Chabner B. A. Paclitaxel in Doxorubicin-Refractory or Mitoxantrone-Refractory Breast Cancer: A Phase I/II Trial of 96-hour Infusion. J. Clin. Oncol. 1994; 12: 1621–1629
   PubMed Web of Science ®Google Scholar
• Seidman A. D., Tiersten A., Hudis C., Gollub M., Barrett S., Yao T-J., Lepore J., Gilewski T., Currie V., Crown J., Hakes T., Baselga J., Sklarin N., Moynihan M. E., Tong W., Egorin M., Kearns C., Spriggs D., Norton L. Phase II Trial of Paclitaxel by 3-hour Infusion as Initial and Salvage Chemotherapy for Metastatic Breast Cancer. J. Clin. Oncol. 1995; 13: 2575–2581
   PubMed Web of Science ®Google Scholar
• Gianni L., Munzone E., Capri G., Spreafico C., Tarenzi E., Fulfaro F., Caraceni A., Martini C., Laffranchi A., Valagussa P., Bonadonna G. Paclitaxel in Metastatic Breast Cancer: A Trial of Two Doses by a 3-hour Infusion in Patients with Disease Recurrence After Prior Therapy with Anthracyclines. J. Natl. Cancer Inst. 1995; 87: 1169–1175
   PubMed Web of Science ®Google Scholar
• Fountzilas G., Athanassiades A., Giannakakis Th., Bafaloukos D., Fahantidis E., Karakousis K., Dombros N., Kosmidis P., Skarlos D. A Phase II Study of Paclitaxel in Advanced Breast Cancer Resistant to Anthracyclines. Eur. J. Cancer, Eur. J. Oncol. 1996; 32A: 47–51
   PubMed Web of Science ®Google Scholar
• Gianni L., Munzone E., Capri G., Fulfaro F., Tarenzi E., Villani F., Spreafic C., Laffranchi A., Caraceni A., Martini C., Stefanelli M., Valagussa P., Bonnadonna G. Paclitaxel by 3-hour Infusion in Combination with Bolus Doxorubicin in Women with Untreated Metastatic Breast Cancer: High Antitumor Efficacy and Cardiac Effects in a Dose-finding and Sequence-finding Study. J. Clin. Oncol. 1995; 13: 2688–2699
   PubMed Web of Science ®Google Scholar
• Gehl J., Boesgaard M., Paaske T., Vittrup Jensen B., Dombernowsky P. Combined Doxorubicin and Paclitaxel in Advanced Breast Cancer: Effective and Cardiotoxic. Ann. Oncol. 1996; 7: 687–693
   PubMed Web of Science ®Google Scholar
• Norton L. Evolving Concepts in the Systemic Drug Therapy of Breast Cancer. Semin Oncol. 1997; 24(suppl 10)3–10
   PubMedGoogle Scholar
• Fountzilas G., Nicolaides C., Aravantinos, et al. Dose-Dense Adjuvant Chemotherapy with Epirubicin Monotherapy in Patients with Operable Breast Cancer and ≥10 Positive Axillary Lymph Nodes. A Feasibility Study. Oncology 1998; 55: 508–512
   PubMed Web of Science ®Google Scholar
• Fountzilas G., Skarlos D., Giannakakis T., Kalogera-Fountzila A., Athanasiades A., Bafaloukos D., Protopsaltis J., Beer M., Pavlidis N., Kosmidis P. Intensive Chemotherapy with High-Dose Epirubicin Every Two Weeks and Prophylactic Administration of Filgastrim. A Phase II Study. Eur. J. Cancer 1994; 30: 965–969
   Google Scholar
• Oken M. M., Greech R. H., Tormey D. C., Horton J., Davis T. E., McFadden E. T., Carbone P. P. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Non Parametric Estimation from Incomplete Observations. J. Am. Stat. Assoc. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Fountzilas G., Athanassiadis A., Giannakakis Th., Briasoulis E., Bafaloukos D., Kalogera-Fountzila A., Onienaoum A., Kalofonos H., Pectasides D., Andreopoulou E., Kosmidis P., Pavlidis N., Skarlos D. A Randomized Study of Epirubicin Monotherapy Every 4 or Every 2 Weeks in Advanced Breast Cancer. Ann. Oncol. 1997; 8: 1213–1220
   PubMed Web of Science ®Google Scholar
• Schwartsmann G., Mans D. R., Menke H. C., Xavier N., Caleffi M., Fabiano A., Filho F., Schunemann H., Kalakun L., Koya R., Pohlman P., Venegas L. F. A Phase II Study of Doxorubicin/Paclitaxel Plus G-CSF for Metastatic Breast Cancer. Oncology 1997; 11(suppl 3)24–29
   PubMedGoogle Scholar
• Amadori D., Frassineti G. L., Zoli W., Milandri C., Serra P., Tienghi A., Ravaioli A., Gentlile A., Salzano E. A Phase I/II Study of Sequential Doxorubicin and Paclitaxel in the Treatment of Advanced Breast Cancer. Semin. Oncol. 1996; 23(suppl 11)16–22
   PubMedGoogle Scholar
• Catimel G., Spielmann M., Dieras V., Kayitalire L., Pouillart P., Guastalla J. P., Soler-Michel P., Graffand N., Garet F., Dumortier A., Pellae-Cosset B., Chazard M. Phase I Study of Paclitaxel and Epirubicin in Patients with Metastatic Breast Cancer: A Preliminary Report on Safety. Semin. Oncol. 1996; 23(suppl 1)24–27
   PubMed Web of Science ®Google Scholar
• Conte P. F., Baldini E., Gennari A., Michelotti A., Salvadori B., Tibaldi C., Danesi R., Innocenti F., Gentile A., Dell'Anna R., Biadi O., Mariani M., Del Tacca M. Dose-finding Study and Pharmacokinetics of Epirubicin and Paclitaxel over 3 Hours: A Regimen with High Activity and Low Cardiotoxicity in Advanced Breast Cancer. J. Clin. Oncol. 1997; 15: 2510–2517
   PubMed Web of Science ®Google Scholar
• Luck H. J., Du Bois A., Thomssen C., Lisboa B., Untch M., Kohler G., Hecker D., Diergarten D. A Phase II Study. Paclitaxel and Epirubicin as First Line Chemotherapy for Patients with Metastatic Breast Cancer. Oncology 1997; 11(suppl 3)34–37
   PubMedGoogle Scholar
• Del Mastro L., Gennari A., Amadori D., Boni C., Brandi M., Conte P. F., Cortesi E., De Lena M., Iacorelli A., Gentile A., Ravaioli A. Paclitaxel Plus Anthracycline as First Line Chemotherapy for Breast Cancer Patients: The Italian Experience. Rationale for Paclitaxel Maintenance Therapy. Proc. Am. Soc. Clin. Oncol. 1998, Abstract No. 523
   Google Scholar
• Rahman Z., Kavanagh J., Champlin R., Giles R., Hanania F., Fu S. Q., Zu Z., Mehra R., Holmes F., Kudelka A., Claxton D., Ellerson D., Calvert L., Dayre A., Halzamayer T., Hamer J., Bachier C., Ostrore J., Przepiorka D., Burtners B., Cote R., Bast R., Hortobagyi G., Deisseroth A. 12 cycles of Paclitaxel Immediately Following High Dose Chemotherapy with Autologous Stem Cell Transplantation Can Induce Complete Remissions in Patients with Advanced Breast and Ovarian Carcinoma. Proc. Am. Soc. Clin. Oncol. 1998, Abstract No. 6293
   Google Scholar
• Sledge G. W., Neuberg D., Jr., Ingle J., Martino S., Wood W. Phase III Trial of Doxorubicin (A) vs Paclitaxel (T) vs Doxorubicin + Paclitaxel (A + T) as First Line Therapy for Metastatic Breast Cancer (MBC): An Intergroup Trial. Proc. Am. Soc. Clin. Oncol. 1997, Abstract No. 2
   PubMedGoogle Scholar